Philogen
Italy - MonteriggioniBiotechnology
Focus: Philogen is a European-headquartered oncology-focused biotechnology company specializing in antibody-cytokine fusion proteins, radioimmunotherapies, and targeted small molecules. The company operates as a public biotech with a diversified pipeline spanning melanoma, glioblastoma, soft tissue sarcoma, and other solid tumors.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Philogen
AI assessmentNot HiringNo open roles listed right now. Follow Philogen to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Peak
Lead Phase 3 asset with dual indication potential; advancement would validate core L19TNF fusion protein platform.
Pipeline & Clinical Trials
Help build intelligence for Philogen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.